Tony's Diary Package — page 1030

IumMWSloctorscity by >2.5 billion tests vaccine resulted in increased neutralizing antibody levels. The data strongly suggest that mixed COVID-19 vaccines could increase protective efficacy against symptomatic SARS-CoV-2 infection. Press release Blurb: NIH clinical trial data strongly suggest that mixed COVID-19 vaccines could increase protective efficacy against symptomatic SARS-CoV-2 infection. Image: FC getting his vaccine? https://www.flickr.com/photos/nihgov/50747919667/in/album72157717478402642/ OR https://www.shutterstock.com/image-photo/black-teen-girl-showsvaccine-mark-1899903244 June 2: Topline results from the ACTIV-1 Immune Modulators clinical trial showed that immune modulator drugs improved survival for people hospitalized with COVID-19. Press release Blurb: ACTIV-1 immune modulators trials meet secondary endpoint/improved survival July 20: The CDC recommended that Novavax's COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older. NIH supported development of the Novavax vaccine, NVX-CoV2373, and is studying it in the "mix & match" trial, where adult volunteers who have been fully vaccinated against COVID-19 receive booster doses of different COVID-19 vaccines to determine the safety and immunogenicity of mixed boosted regimens. Blurb: CDC recommended Novavax vaccine for adults Image: https://www.shutterstock.com/image-photo/novavax-coronavirus-vaccine-doctorsnurses-hands-1904970715 April 29: Two years after its launch, RADx-supported companies increased cumulative U.S. capacity by >2.5 billion tests, helping drive a national paradigm shift where over the counter (home) and point of care tests become the dominant form of testing. Blurb: After two years, RADx-supported companies increased U.S. capacity by >2.5 billion tests Image: 4.29.22 RADx test capacity Monkey pox cases in the UK starting to trend downward: